T he efficient and specific stimulation of T cell responses is a priority in current vaccine research. Solutions to many unresolved problems of vaccine development against human diseases such as AIDS, tuberculosis, papilloma and herpes virus infection, chronic hepatitis B and C, and cancer, are expected to depend on the specific priming of MHC class I-and class II-restricted T cell responses against the relevant pathogen (1). Current approaches to design T cell-stimulating vaccines are based on novel adjuvants, synthetic peptides, recombinant viruses, or DNA vaccines.
With the availability of the complete sequence of the genomes of many major pathogens, the choice of Ags (and their immunogenic epitopes) has been strikingly expanded. Vaccines incorporating multiple, antigenic peptides binding to either MHC class II molecules (stimulating CD4 ϩ Th cell responses) or class I molecules (stimulating CD8 ϩ CTL responses) are an attractive choice for stimulating cellular immunity (2) . This can focus CTL responses to multiple target Ags and/or multiple epitopes of a target Ag, and can provide help for priming CTL responses by codelivering class II-restricted T cell effector functions. By eliminating suppressive or immunodominant epitopes and optimizing MHC binding affinity and TCR contact, the immunogenicity of such synthetic peptide vaccines can be increased considerably.
Multiepitope vaccines can be constructed as either a synthetic peptide vaccine or as a DNA vaccine (or an expression cassette cloned into the genome of a recombinant virus). If the length of the peptide is Ͼ50 -80 residues, the DNA-based approach is easier for vaccine designs, at least at the stage of experimental, preclinical vaccine designs. We therefore exploited the DNA vaccination approach to test in the mouse some aspects relevant for the design of optimal CTL-stimulating, multiepitope vaccines. Long peptides representing linear constructs of multiepitope or polytope vaccines have higher intrinsic immunogenicity than mixtures of individual peptides, although they require processing for acquiring T cell stimulatory potency (3, 4) . Although combinations of epitopes can create new junctional epitopes (that are irrelevant for antipathogen immunity), their disruption by appropriate spacers between epitopes can solve this problem (4) . Furthermore, the combination of a multitude of antigenic epitopes may establish novel immunodominance hierarchies that limit the immunogenicity of the subdominant epitopes. This can be overcome by codelivering an appropriate adjuvant (as shown in this report).
The N-terminal domain of the SV40 large tumor Ag (T-Ag) 3 associates with the stress protein 73-kDa heat shock protein (hsp73) through a DnaJ-like structure, i.e., the J domain (5-9). T-Ag associates with hsp73 through the conserved HPD motif and the ␣-helical structure of the J domain. We have reported that different mutant T-Ags show stable association with hsp73 if their N terminus is intact (10 -14) . The N-terminal domain of T-Ag required for hsp73 association is located within the T 77 (but not the T 60 ) fragment that hence contains the intact J domain (15) . From this observation we derived a vector system for the efficient expression of hsp73-associated, chimeric proteins (12, 13, (15) (16) (17) . In this system the T-Ag-derived J domain is fused N-terminally to different sequences from heterologous viral Ags of different origins and lengths. This allowed us to design DNA vaccines that stably express chimeric, hsp73-binding proteins at a high level. In addition to enhancing expression, hsp70 molecules are innate adjuvants that enhance and modulate the immunogenicity of protein and peptide Ags (reviewed in Refs. 18 -20) . The adjuvant effect of hsp molecules seems to have many facets. Hsp induces the migration and maturation (including cytokine/chemokine release) of dendritic cells (DC) (21) (22) (23) (24) (25) (26) (27) . Hsp facilitates the priming of CD8 ϩ T cell responses to peptides from tumor Ags, minor H Ags, or viruses by delivering them to processing pathways for MHC class I-restricted presentation (26, 28 -39) . Hsp is thus an attractive innate adjuvant in vaccine formulations to enhance its immunogenicity for CTL. We compare the immunogenicity of multiepitope DNA vaccines for CD8 ϩ T cells that express Ag associated or not associated with hsp73.
Materials and Methods

Mice
, F 1 (BALB/c ϫ C57BL/6) mice, and F 1 (dm2 ϫ C57BL/6) mice were bred and kept under standard pathogen-free conditions in the animal colony of Ulm University (Ulm, Germany 
Vector constructs
The 106-residue murine polytope sequence ( Fig. 1 ) was obtained from a pt10-encoding Bluescript construct with primers (GAATTCATAT GTCTAGAGCCAGCAACGAGAACATG ϩ; generating an EcoRI site) and (GGTACCTAAGTGCTCGGGGCCGGACACϪ; generating a KpnI site) and was cloned directly into a pEGFP N1 (Clontech, Palo Alto, CA; catalogue no. 6085-1)-based mammalian pCMV expression vector, generating the plasmid pCMV/pt10. In this vector Ags are expressed under human CMV promoter/enhancer control. Construction of the vectors encoding the SV40 T-Ag derived T 60 or T 77 fragments ( pBlue/T 60 and pBlue/ T 77 ) has been described (12, 14, 15, 40) . The T 60 -and T 77 -encoding sequences were cloned into the pCMV expression vector, generating plasmids pCMV/T 77 and pCMV/T 60 . The pt-10-encoding EcoRI-KpnI fragment was cloned C-terminally (in-frame) into plasmids pCMV/T 77 and pCMV/T 60 , generating plasmids pCMV/T 77 -pt10 and pCMV/T 60 -pt10, respectively.
Expression of polytope constructs by transfected cells
LMH cells were transiently transfected with plasmid DNA using the Ca 2 PO 4 method. Briefly, 10 g of plasmid DNA was adjusted to 0.25 M CaCl 2 in a volume of 500 l and mixed with 500 l of 2ϫ HBS buffer (280 mM NaCl, 1.5 mM Na 2 HPO 4 , and 50 mM HEPES, pH 7.1). Semiconfluent cell monolayers were incubated with the DNA solution for 12 h. Cells were metabolically labeled for 12-15 h with [ 35 S]methionine 36 h after transfection, extracted with lysis buffer (120 mM NaCl, 1% aprotinin (Trasylol, Bayer, Leverkusen, Germany), leupeptin, 0.5% Nonidet P-40, and 50 mM Tris-hydrochloride (pH 8.0)) for 30 min at 4°C. Extracts were cleared by centrifugation and immunoprecipitated for T-Ag using the mAb PAB108 and protein A-Sepharose. Immune complexes bound to protein A-Sepharose were purified with wash buffer (300 mM LiCl, 1% Nonidet P-40, and 100 mM Tris-hydrochloride, pH 8.5), followed by two washes in PBS and 0.1ϫ PBS. Immune complexes were recovered from protein A-Sepharose with elution buffer (1.5% SDS, 5% ME, and 7 mM Tris-hydrochloride, pH 6.8), processed for SDS-PAGE, and analyzed by fluorography.
DNA vaccination
For i.m. nucleic acid immunization, we injected 50 l of PBS containing 1 g/l of plasmid DNA into each tibialis anterior muscle as previously described (12, 41) . Intradermal injection of 2 g of particle-coated DNA with the Helios Gene Gun system (catalogue no. 165-2431; Bio-Rad, Munich, Germany) has been described (14, 15) , with the modification that immunization was performed with two shots of 300 psi.
Peptides
Synthetic peptides 1, 2, 3, 5, 6, 7, 8, and 10 listed in Fig. 1 were obtained from Jerini BioTools (Berlin, Germany). Peptides were dissolved in a DMSO stock solution at a concentration of 10 mg/ml and were diluted with culture medium before use.
Determination of splenic CD8 ϩ T cell frequencies
Spleen cells (1 ϫ 10 7 /ml) were incubated for 1 h in RPMI 1640 medium with 0.1 g/ml of the respective peptide. Thereafter, 5 g/ml brefeldin A (BFA; Sigma-Aldrich, St. Louis, MO; catalogue no. 15870) was added, and the cultures were incubated for an additional 4 -6 h. Cells were harvested and surface-stained with PE-conjugated anti-CD8 mAb (BD PharMingen, San Diego, CA; catalogue no. 01045B). Surface-stained cells were fixed with 2% paraformaldehyde in PBS before intracellular staining for IFN-␥. 
Results
Priming multispecific, murine CD8 ϩ T cell responses by polytope DNA vaccines
The plasmid pCMV/pt10 encodes 10 well-characterized epitopes binding to murine MHC class I molecules encoded by the K, D, or L locus of H-2 d , H-2 b , and H-2 k haplotype mice. Fig. 1 lists these 10 epitopes, their amino acid sequences, the protein Ag and the pathogens from which they are derived, and the restricting MHC class I molecules that bind the epitope. The pt10 DNA vaccine has been shown to prime multispecific, murine CTL responses (42) .
We injected 100 g of pCMV/pt10 DNA i.m. into H-2 b (C57BL/6, B6; Fig. 2A ) or H-2 d (BALB/c) mice (Fig. 2B) . No , and H-2 k -restricted CD8 ϩ T cell epitopes. The amino acid sequences, the protein Ags and the pathogens from which they are derived, and the restricting MHC class I molecules that bind the epitopes are shown. TS, two spacer residues between epitopes 5 and 6. The C-terminal 11 residues represent an Ab-binding epitope (42 ϩ T cells to other epitopes of the construct, apparently regardless of their restriction or the nature of the epitope.
We immunized F1 (B6 ϫ BALB/c) mice (Fig. 2D) to test whether the pt10 DNA vaccine can coprime multispecific, H-2 band H-2 d -restricted CD8 ϩ T cell responses. Compared with vaccinated B6 mice, the H-2 b -restricted CD8 ϩ T cell responses to epitopes 1, 2, 6, and 7 were deficient in F 1 (B6 ϫ BALB/c) mice (Fig. 2, A and D) . The H-2 d -restricted CD8 ϩ T cell responses against epitopes 3, 5, 8, and 10 primed in BALB/c and F 1 (B6 ϫ BALB/c) mice were comparable (Fig. 2, B and D) . When L dϪ F 1 (B6 ϫ dm2) mice were used instead of F 1 (B6 ϫ BALB/c) mice, efficient priming of CD8 ϩ T cell responses to H-2 b -restricted epitopes 1, 2, 6, and 7 and K d -restricted epitopes 3 and 8 was observed (Fig. 2E) . These data indicate that 1) the pt10 DNA vaccine can efficiently coprime multispecific CD8 ϩ T cell responses restricted by at least four different MHC class I molecules; and 2) priming of L d -restricted CD8 ϩ T cell responses can down-regulate copriming of CD8 ϩ T cells to epitopes restricted by unrelated MHC class I molecules.
cell responses, not Ld surface expression, down-modulate copriming of CD8 ϩ T cells restricted by unrelated MHC class I molecules
The K b -restricted, OVA epitope 2 (SIINFEKL)-specific CD8 ϩ T cell responses were efficiently elicited by the pCMV/OVA DNA vaccine (encoding the complete OVA sequence) in B6 mice, F 1 (B6 ϫ dm2) mice, and F 1 (B6 ϫ BALB/c) mice ( Fig. 3A; groups ϩ T cells specific for this epitope were efficiently primed by the pt10-encoding DNA vaccine in B6 and F 1 (B6 ϫ dm2) mice, but not in F 1 (B6 ϫ BALB/c) mice (Figs. 2 and 3B ). Hence, copriming L d -restricted CD8 ϩ T cell responses against epitopes encoded by pt10 (see Fig. 2 ), but not the surface expression of L d , down-modulates copriming of CD8 ϩ T cell to other epitopes restricted by unrelated MHC class I molecules and present on the same antigenic construct.
Construction of an hsp73-associated polytope DNA vaccine
The pt10 vaccine used primed some CD8 ϩ T cell responses inefficiently. We tested whether alternative designs of the pt10 DNA vaccine enhance the efficiency of multispecific CD8 ϩ T cells priming by this construct and can overcome the suppressive effect of L d -restricted CD8 ϩ T cell priming. We used an hsp73-mediated expression system (14, 15) by fusing the hsp73 binding SV40 TAg-derived DnaJ domain N-terminally in-frame to the polytopeencoding DNA sequence. The 106-residue-encoding pt10 sequence was fused C-terminally to the hsp73-binding, 77-residue, N-terminal T-Ag fragment, to generate the cT 77 -pt10 chimeric protein (Fig. 4) . As a negative control, the T 60 N terminus of the T-Ag that does not bind hsp73 (14, 15) was fused to the pt10 sequence to generate the non-hsp-binding fusion protein T 60 -pt10 (Fig. 4) . The expression of the fusion proteins from the expression constructs pCMV/T 77 -pt10 and pCMV/T 60 -pt10 was tested after transient transfection of LMH (chicken hepatoma) cells. The mAb 108 (directed against the extreme N terminus of the T-Ag) was used for immunoprecipitation of chimeric Ags from the lysates of the transfectants. Subsequent SDS-PAGE analyses revealed efficient expression of the T 77 -pt10 fusion protein (Fig. 4) . We barely detected the non-hsp-associated T 60 -pt10 fusion protein (Fig. 4) , confirming our observation that stress protein-associated expression of the peptide was always higher than the expression of the corresponding non-hsp73-associated, chimeric proteins (14, 15) . The hsp73 stress protein was coprecipitated with the fusion protein from transfected cells expressing peptides encoded by pCMV/T 77 -pt10, but not from transfected cells expressing peptide encoded by pCMV/T 60 -pt10 (Fig. 4) . This confirms that the tight, noncovalent association between hsp73 and the viral DnaJ domain requires the intact 77-residue domain as described by us in other Ag systems (10, 11, 13, 15, 16) . Hence, we have constructed DNA vaccines carrying the immunogenic pt10 domain, but differing in the level of expression and the association with hsp73.
Hsp-associated expression of polytope vaccines facilitates copriming of multispecific CD8
ϩ T cell responses F 1 (B6 ϫ BALB/c) mice were immunized by a single i.m. injection of the DNA vaccines pCMV/pt10 ( Fig. 5; group a) , pCMV/ T 77 -pt10 (group b), and pCMV/T 60 -pt10 (group c). The primed CD8 ϩ T cell responses were read out against the H-2 b -restricted, pt10-encoded epitopes 1, 2, 6, and 7 ( Fig. 5A ) and against the H-2 d -restricted epitopes 3, 5, 8, and 10 ( Fig. 5B) . The hsp73-associated expression of the polytope DNA vaccine (group b) was reproducibly superior to the non-hsp-associated expression of the same DNA vaccine (group c) in priming all multispecific CD8 ϩ T cell responses tested. No reproducible differences in the relative efficacy of CD8 ϩ T cell priming were detectable between vaccinations with the conventional pt10 vaccine (group a) and the pCMV/T 60 -pt10 vaccine (group c). The expression of antigenic domains in tight, noncovalent association with hsp73 thus enhances their immunogenicity for CD8 ϩ T cells. Comparable CD8 ϩ T cell responses to the different epitopes were primed in F 1 (B6 ϫ BALB/c) and F 1 (B6 ϫ dm2) mice (Fig. 6 , compare groups b and c). Thus, priming to L d -restricted epitopes by the pt10 vaccine, but not the T 77 -pt10 vaccine, down-modulated copriming to other CD8 ϩ T cell responses. The efficacy of hsp73-binding T 77 -pt10 Ag to specifically prime pt10-specific CD8 ϩ T cell precursors was even more striking in gene gun-mediated, intradermal DNA vaccination (Fig. 7) . While priming of IFN-␥-producing, pt10-specific CD8 ϩ T cell responses was not detectable after injection of DNA vaccines encoding the non-hsp-binding pt10 (group a) or T 60 -pt10 construct (group c), they were readily detectable after intradermal injection of the hsp73-binding T 77 -pt10-encoding plasmid DNA with the gene gun (group b). The association of Ag with hsp73 thus strikingly enhances its immunogenicity for CD8 ϩ T cell precursors, supporting CD8 ϩ T cell priming even after intradermal delivery of low doses of DNA vaccines. Hence, a high level of Ag expression in association with hsp73 efficiently induces pt10-specific CD8 ϩ T cell responses even under L d -dependent immunodominance, thereby facilitating copriming of CD8 ϩ T cell populations with a diverse repertoire.
Discussion
For this study we constructed DNA vaccines that express the polytope sequence pt10. This chimeric Ag was expressed in a form that either stably bound the constitutively expressed, cytosolic hsp73 molecule or was not hsp bound. As every nascent protein emerging from the ribosome transiently binds hsp73, it seems that the DnaJhomologous sequence in the nascent polytope protein delays the off rate of hsp. As the DnaJ homologous sequence is present in the N terminus of native as well as mutant T-Ag, and only mutant, not native, T-Ag shows stable hsp73 binding, additional downstream signals (such as accessible epitopes bound by hsp73 substrate binding sites) seem to be required for stable hsp binding. Alternatively, specific post-translational capture of the chimeric, cytosolic protein by hsp73 to target it for alternative, endolysosomal degradation may operate in this system (43) (44) (45) . The long half-life of the hsp73/protein complexes may reflect their delayed clearance from the cytosol and/or their extended survival in an endolysosomal compartment. The data in Fig. 4 confirm that stable hsp73 binding allows the expression of protein fragments, which difficult to achieve without hsp binding (12, 15) . This offers the chance to express selected immunogenic domains from different protein Ags of interest. The limits of the carrying capacity of the system are not yet clear, but up to 800 residues have been successfully expressed in the system (R. Schirmbeck, manuscript in preparation). This would allow the incorporation of long spacer regions (to block generation of junctional epitopes) (4) or long flanking regions (to facilitate natural processing of the epitope) into a construct. Hence, the system may overcome some of the restrictions in size and heterogeneity inherent in conventional peptide-based approaches.
The use of the chimeric Ag certainly is not restricted to DNA vaccination, but preparative isolation of hsp73/chimeric protein complexes is a feasible option, as has been expertly demonstrated for hsp/peptide complexes (33, 46 -48) . In addition to facilitating expression, hsp binding offers other features that make it attractive as a vaccine. Hsp molecules of the hsp70 and hsp90 class are intrinsic adjuvants (as indicated above) and introduce cytosolic proteins into alternative processing pathways (10, 11) . As different proteolytic systems seem to give rise to different, although overlapping, repertoires of antigenic epitopes (49) , this means of expression can potentially extend the repertoire of immunogenic epitopes presented by an Ag.
We and others have described the immunodominance of the L d -restricted CD8 ϩ T cell response that interferes with the copriming of CD8 ϩ T cells restricted by other MHC class I molecules in the HBsAg system (17, 50) . These data are extended in this report. Two additional L d -restricted epitopes from two unrelated viruses, i.e., murine CMV and lymphocytic choriomengitis virus, showed a similar immunodominance. This implies either that immunodominance is a property of L d -restricted CD8 ϩ T cell responses or that we detected by chance three independent examples of immunodominant L d -restricted CD8 ϩ T cell responses. Detailed analysis of L d -restricted CD8 ϩ T cell responses in other systems may provide an answer. The cellular and molecular mechanisms that mediates this suppression are unknown, but are under active study in our group. It can be overcome at least partially by supplying high doses of type I IFNs and/or IL-15 to the site where CD8 ϩ T cell precursors are primed in situ (51) . This suggests the involvement of a factor-mediated immunoregulation. Further studies are needed to elucidate this phenomenon.
We have previously described and reiterated above the potential advantages of delivery of hsp-bound Ag as vaccines. These include enhanced expression and facilitated expression of even large chimeric proteins (when used as a DNA vaccine), its facilitation of cross-priming, and its ability to introduce Ags into alternative processing pathways. The expression of the polytope vaccine as hspbinding complexes not only enhanced its immunogenicity, but at least partially overcame the suppressive effect of L d -dependent immunodominance. This may be related to the adjuvant effect of hsp, e.g., its cytokine-releasing effect. Taken together, these data support the idea that hsp-bound, large protein Ags produced in situ by DNA vaccines display exceptional immunogenicity and can escape suppressive immunoregulation.
